COTA and Texas Oncology partner to leverage AI for better data insights

COTA and Texas Oncology’s Precision Health Informatics collaborate to use AI in transforming healthcare data into actionable insights, enhancing precision medicine and cancer care.

COTA, Inc., in partnership with Texas Oncology’s Precision Health Informatics, LLC (PHI), have announced a collaboration to enhance precision medicine across Texas Oncology’s community cancer centers. Utilizing COTA’s AI-powered curation engine, CAILIN™, this partnership aims to transform fragmented healthcare data into actionable insights, improving the quality of cancer care.

COTA, founded by oncologists, focuses on precise, patient-first cancer care using real-world data (RWD). Their analytics platform collaborates with life sciences companies, healthcare providers, and payers to improve cancer treatment.

Electronic health records (EHRs) provide a detailed account of a patient’s cancer care journey. However, their unstructured and incomplete nature presents challenges for effective analysis. By incorporating AI into data processing, COTA and PHI seek to overcome these challenges and expedite the implementation of precision medicine at the point of care. This integration aims to streamline data curation, giving oncologists timely and relevant information to tailor treatments more effectively.

A robust data foundation is essential for the success of AI-driven healthcare initiatives. Lori Brisbin, Chief Operating Officer of Precision Health Informatics, emphasizes this point,

“As we invest in AI, a solid data foundation is crucial. COTA’s AI-powered curation engine enables Texas Oncology to derive meaningful insights and deliver personalized care to patients.”

Ensuring the accuracy and cleanliness of data guarantees that the insights generated are reliable and actionable, ultimately benefiting patient outcomes.

The collaboration between COTA and PHI also explores the potential of generative AI in advancing cancer care. Dr CK Wang, Chief Medical Officer at COTA, notes,

“By meshing automation and supervision of high-quality RWD, COTA is changing the dynamics of cancer care.”

Integrating generative AI with RWD allows for continuous improvement of treatment protocols and the development of innovative cancer therapies tailored to the unique needs of patients.

PHI, a subsidiary of Texas Oncology, leverages patients’ genetic information to drive cancer testing and treatment. Texas Oncology, with over 530 physicians and 280 locations, provides comprehensive, community-based cancer care. The organization’s clinical trials and research programs have significantly contributed to the approval of more than 100 FDA-approved cancer therapies.